Sartini Davide, Muzzonigro Giovanni, Milanese Giulio, Pierella Francesca, Rossi Valentina, Emanuelli Monica
Institute of Biochemical Biotechnologies, Azienda Ospedaliero-Universitaria Umberto I-Lancisi-Salesi, Ancona, Italy.
J Urol. 2006 Nov;176(5):2248-54. doi: 10.1016/j.juro.2006.07.046.
To explore the involvement of enzymes of drug metabolism in renal cell carcinoma we analyzed the gene expression profiles of tumor and nontumor tissues from the same patient by DNA macroarray. The enzyme nicotinamide N-methyltransferase was selected for further evaluation.
Nicotinamide N-methyltransferase mRNA expression was investigated in paired tissue samples from cancerous and noncancerous parts of the kidneys of 30 patients with clear cell renal cell carcinoma who underwent tumor nephrectomy. Measurements were performed by semiquantitative reverse transcriptase-polymerase chain reaction and quantitative real-time polymerase chain reaction. Paired tissue samples were also obtained from 1 patient with chromophobe renal cell carcinoma and from another with oncocytoma to compare the specificity of changes in nicotinamide N-methyltransferase expression among tumors that are related to different renal epithelial cell types. Western blot analysis and catalytic activity assay were also performed to study nicotinamide N-methyltransferase expression. Expression correlated with tumor characteristics.
A marked increased expression in tumor tissue was found for nicotinamide N-methyltransferase, which is an enzyme involved in the biotransformation of many drugs and xenobiotic compounds. Differential gene expression measurements in tumor vs normal tissue revealed up-regulation in all clear cell renal cell carcinomas at between 3 and 294-fold (mean 41). In contrast, in chromophobe renal cell carcinoma and oncocytoma nicotinamide N-methyltransferase expression did not increase. In addition, nicotinamide N-methyltransferase expression significantly correlated inversely with tumor size.
Our results indicate that a marked nicotinamide N-methyltransferase increase is a peculiar feature of clear cell renal cell carcinoma. Additional studies may establish the role of nicotinamide N-methyltransferase in tumor formation and progression.
为了探究药物代谢酶在肾细胞癌中的作用,我们通过DNA宏阵列分析了同一患者肿瘤组织和非肿瘤组织的基因表达谱。选择烟酰胺N-甲基转移酶进行进一步评估。
对30例接受肿瘤肾切除术的透明细胞肾细胞癌患者肾脏癌组织和非癌组织的配对样本进行烟酰胺N-甲基转移酶mRNA表达研究。采用半定量逆转录聚合酶链反应和定量实时聚合酶链反应进行检测。还从1例嫌色细胞肾细胞癌患者和另1例嗜酸细胞瘤患者获取配对组织样本,以比较与不同肾上皮细胞类型相关的肿瘤中烟酰胺N-甲基转移酶表达变化的特异性。同时进行蛋白质免疫印迹分析和催化活性测定以研究烟酰胺N-甲基转移酶的表达。其表达与肿瘤特征相关。
发现肿瘤组织中烟酰胺N-甲基转移酶的表达显著增加,该酶参与多种药物和外源性化合物的生物转化。肿瘤组织与正常组织的差异基因表达测量显示,所有透明细胞肾细胞癌中该酶上调3至294倍(平均41倍)。相比之下,嫌色细胞肾细胞癌和嗜酸细胞瘤中烟酰胺N-甲基转移酶的表达未增加。此外,烟酰胺N-甲基转移酶的表达与肿瘤大小显著负相关。
我们的结果表明,烟酰胺N-甲基转移酶显著增加是透明细胞肾细胞癌的一个独特特征。进一步的研究可能会确定烟酰胺N-甲基转移酶在肿瘤形成和进展中的作用。